ivermectin - versus control - for COVID-19 pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

deaths 0.33 [0.16, 0.69]< 10%4 studies (4/-)99.8 %highnot evaluable lowcrucial-
clinical deterioration 0.45 [0.26, 0.80]< 10%3 studies (3/-)99.7 %highnot evaluable lowimportant-
clinical improvement 1.67 [1.05, 2.66]> 10%3 studies (3/-)98.5 %highnot evaluable lowimportant-
clinical improvement (7-day) 1.82 [1.23, 2.69]> 10%2 studies (2/-)99.9 %highnot evaluable lowimportant-
clinical improvement (time to event analysis only) 1.89 [1.06, 3.38]> 10%1 study (1/-)98.4 %highnot evaluable lowimportant-
PCR-negative conversion 0.92 [0.77, 1.09]> 10%2 studies (2/-)16.4 %highnot evaluable lowimportant-
PCR-negative conversion (14-day) 4.10 [1.12, 14.99]> 10%1 study (1/-)98.3 %highnot evaluable lowimportant-
PCR-negative conversion (7-day) 0.92 [0.77, 1.09]> 10%1 study (1/-)17.3 %lownot evaluable highimportant-
PCR-negative conversion (time to event analysis only) 4.10 [1.12, 14.99]> 10%1 study (1/-)98.3 %highnot evaluable lowimportant-
ventilation 0.42 [0.02, 7.39]< 10%1 study (1/-)72.0 %some concernnot evaluable moderateimportant-

safety endpoints 00

serious adverse events 2.14 [0.21, 21.56]< 10%2 studies (2/-)26.0 %highnot evaluable lowimportant-
adverse events 1.97 [0.55, 7.04]< 136%3 studies (3/-)15.0 %highnot evaluable lownon important-

LoD: level of demonstration ( demonstrated, suggested, inconclusive, safety concerns);
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.